Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Current Clinical Pharmacology
|
April 22, 2010
Inducing synthetic lethality using PARP inhibitors
David S Boss, Jos H Beijnen, Jan H M Schellens
The Oncologist
|
August 18, 2009
Clinical experience with aurora kinase inhibitors: a review
David S Boss, Jos H Beijnen, Jan H M Schellens
Journal of Patient Safety
|
April 9, 2025
Antecedents and Outcomes of Physician Coworker Conflict: A Differential Occupational Model for Health Care Managers
Eung Il Kim, Benjamin B Dunford, Wayne Boss, et al.
Family Practice
|
October 4, 2017
Influence of point-of-care C-reactive protein testing on antibiotic prescription habits in primary care in the Netherlands
Tim J Schuijt, David S Boss, Ruben E A Musson, et al.
Health Care Management Review
|
December 21, 2017
Work-family culture within hospitals: An interdepartmental analysis of employee engagement and retention
Matthew B Perrigino, Benjamin B Dunford, Matt Troup, et al.
The Oncologist
|
February 5, 2008
Application of PET/CT in the development of novel anticancer drugs
David S Boss, Renato Valdes Olmos, Michiel Sinaasappel, et al.
Interactive Cardiovascular and Thoracic Surgery
|
August 3, 2007
Malondialdehyde in plasma, a biomarker of global oxidative stress during mini-CABG compared to on- and off-pump CABG surgery: a pilot study
Wim B Gerritsen, Wim-Jan P van Boven, David S Boss, et al.
Tumori
|
May 3, 2011
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report
David S Boss, Hilary Glen, Jos H Beijnen, et al.
Analytical Biochemistry
|
May 26, 2009
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma
Carola W N Damen, Els R de Groot, Marianne Heij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 18, 2009
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors
David S Boss, Wandena S Siegel-Lakhai, Nadja E van Egmond-Schoemaker, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Current Clinical Pharmacology
|
April 22, 2010
Inducing synthetic lethality using PARP inhibitors
David S Boss, Jos H Beijnen, Jan H M Schellens
The Oncologist
|
August 18, 2009
Clinical experience with aurora kinase inhibitors: a review
David S Boss, Jos H Beijnen, Jan H M Schellens
Journal of Patient Safety
|
April 9, 2025
Antecedents and Outcomes of Physician Coworker Conflict: A Differential Occupational Model for Health Care Managers
Eung Il Kim, Benjamin B Dunford, Wayne Boss, et al.
Family Practice
|
October 4, 2017
Influence of point-of-care C-reactive protein testing on antibiotic prescription habits in primary care in the Netherlands
Tim J Schuijt, David S Boss, Ruben E A Musson, et al.
Health Care Management Review
|
December 21, 2017
Work-family culture within hospitals: An interdepartmental analysis of employee engagement and retention
Matthew B Perrigino, Benjamin B Dunford, Matt Troup, et al.
The Oncologist
|
February 5, 2008
Application of PET/CT in the development of novel anticancer drugs
David S Boss, Renato Valdes Olmos, Michiel Sinaasappel, et al.
Interactive Cardiovascular and Thoracic Surgery
|
August 3, 2007
Malondialdehyde in plasma, a biomarker of global oxidative stress during mini-CABG compared to on- and off-pump CABG surgery: a pilot study
Wim B Gerritsen, Wim-Jan P van Boven, David S Boss, et al.
Tumori
|
May 3, 2011
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report
David S Boss, Hilary Glen, Jos H Beijnen, et al.
Analytical Biochemistry
|
May 26, 2009
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma
Carola W N Damen, Els R de Groot, Marianne Heij, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 18, 2009
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors
David S Boss, Wandena S Siegel-Lakhai, Nadja E van Egmond-Schoemaker, et al.
Page
of 2